SCHEMBL24928666

SCHEMBL24928666

COC(=O)c1cc(N)c(C2CC2)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 7/20 0.41
CFTR P13569 4/20 0.41
GAA P10253 5/20 0.41
HSD17B10 Q99714 4/20 0.41
HPGD P15428 4/20 0.41
MAPT P10636 3/20 0.41
GLA P06280 2/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
ATM Q13315 1/20 0.41
TSHR P16473 2/20 0.40
ABL1 P00519 1/20 0.40
SLC6A3 Q01959 1/20 0.39
ALOX15 P16050 1/20 0.39
PDK2 Q15119 1/20 0.38
PDK4 Q16654 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SCN9A Q15858 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21232435 0.82 CFTR (0.49) KDM4EALDH1A1CFTRGAAHSD17B10
SCHEMBL16759241 0.81 TSHR (0.41) KDM4EALDH1A1GAAHSD17B10HPGD
SCHEMBL24928665 0.80 ALDH1A1 (0.42) ALDH1A1HSD17B10HPGDTSHRSCN9A
SCHEMBL1509484 0.80 KDM4E (0.52) KDM4EALDH1A1CFTRGAAHSD17B10
SCHEMBL24518545 0.79 CFTR (0.47) ALDH1A1CFTRHSD17B10HPGDTSHR
SCHEMBL30221910 0.79 KDM4E (0.50) KDM4EALDH1A1CFTRGAAHSD17B10
SCHEMBL2900514 0.79 KDM4E (0.59) KDM4EALDH1A1CFTRGAAHSD17B10
SCHEMBL3529864 0.79 KDM4E (0.50) KDM4EALDH1A1CFTRGAAHSD17B10
SCHEMBL8578049 0.78 ALDH1A1 (0.43) ALDH1A1HSD17B10HPGDTSHRSCN9A
SCHEMBL12686869 0.78 KDM4E (0.43) KDM4EALDH1A1CFTRGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376046-A1 PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-11-14 US disclosed
EP-4376955-A1 PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS Grey Wolf Therapeutics Limited (GB) 2024-06-05 EP disclosed
CN-117881657-A Phenyl-sulfamoyl-benzoic acid derivatives as ERAP1 modulators 格雷沃尔夫治疗有限公司 2024-04-12 CN disclosed
WO-2023007188-A1 PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS Grey Wolf Therapeutics Limited (GB) 2023-02-02 WO disclosed
WO-2023007188-A1 PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS Grey Wolf Therapeutics Limited (GB) 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376046-A1 PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS ERAP1, XPO1, RRP15 KDM4E 1427/4885ALDH1A1 2435/4885CFTR 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.